People

Laura Stoppel

Nimbus Therapeutics director and biotechnology investor with neuroscience research training; has investment experience at RA Capital Management spanning cell therapies, retinal disorders and neurodevelopmental diseases. Current source-verified RA affiliation: Laura Stoppel holds the source-published role of Partner within RA Capital Management’s Healthcare group. The individual directory reports joining in2016; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: Harvard University, Massachusetts Institute of Technology. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.